ePrivacy and GPDR Cookie Consent by Cookie Consent

The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma


Nov. 12, 2019


Preclinical models and clinical data suggest differential drug sensitivities for different EGFR exon 19 indels, with the rarer EGFR L747_A750delinsP mutation showing reduced sensitivity to erlotinib & osimertinib but high sensitivity to afatinib.